Alby Elias

ORCID: 0000-0002-7494-1028
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Electroconvulsive Therapy Studies
  • Traumatic Brain Injury and Neurovascular Disturbances
  • Sarcoma Diagnosis and Treatment
  • Cancer Treatment and Pharmacology
  • Treatment of Major Depression
  • Traumatic Brain Injury Research
  • Neuroendocrine Tumor Research Advances
  • HER2/EGFR in Cancer Research
  • Monoclonal and Polyclonal Antibodies Research
  • Chemotherapy-induced organ toxicity mitigation
  • Dementia and Cognitive Impairment Research
  • Lung Cancer Research Studies
  • Breast Cancer Treatment Studies
  • Cancer therapeutics and mechanisms
  • Bipolar Disorder and Treatment
  • Obstructive Sleep Apnea Research
  • Lymphoma Diagnosis and Treatment
  • Neuroblastoma Research and Treatments
  • Intensive Care Unit Cognitive Disorders
  • Frailty in Older Adults
  • Sleep and Wakefulness Research
  • Perfectionism, Procrastination, Anxiety Studies
  • Acute Myeloid Leukemia Research
  • Sleep and related disorders
  • Schizophrenia research and treatment

The University of Melbourne
2014-2025

Western Health
2025

Austin Health
2015-2023

Melbourne Health
2019-2023

The Royal Melbourne Hospital
2022-2023

Columbia University
2020

Florey Institute of Neuroscience and Mental Health
2017-2019

Sunshine Hospital
2019

Western Hospital
2019

Commonwealth Scientific and Industrial Research Organisation
2017

European and American investigators have reported response rates of 38% to 83% for ifosfamide alone in pretreated sarcomas. In a phase II trial 2.0g/m2 days 1 4 with mesna uroprotection 124 patients previously failed sarcomas, four (3%) responded completely (95% exact confidence interval, 1% 8%) 26 (21%) had complete or partial 14% 29%). The median time progression was 5 9 months responders, respectively. the subset soft tissue rate receiving bolus administration 26%, compared 9% continuous...

10.1200/jco.1989.7.1.126 article EN Journal of Clinical Oncology 1989-01-01

A series of 33 patients were treated with a four-day continuous infusion carboplatin in phase I study to determine the maximum-tolerated dose (MTD) this agent when used autologous bone marrow reinfusion. Doses escalated from 375 2,400 mg/m2; reinfusion was added regimen at doses 1,600 mg/m2 and above. The MTD determined be 2,000 mg/m2. Dose-limiting toxicity consisting reversible hepatotoxicity, renal dysfunction, moderate severe ototoxicity observed There ten responses 31 heavily pretreated...

10.1200/jco.1989.7.5.651 article EN Journal of Clinical Oncology 1989-05-01

Background: An association between obstructive sleep apnea (OSA) and Alzheimer's disease has been suggested but little is known about amyloid-β tau deposition in this syndrome. Objective: To determine amyloid burden cognitive function OSA comparison with those without a diagno sis of OSA. Methods: The status was determined by asking participants history polysomnographic diagnosis the use Continuous Positive Airway Pressure (CPAP). A comprehensive neuropsychological battery measured function....

10.3233/jad-180640 article EN Journal of Alzheimer s Disease 2018-10-09

PURPOSE With a median observation time of 50 months from transplant, 13 (22%) 62 women with metastatic breast cancer treated high-dose chemotherapy at the Dana-Farber Cancer Institute (DFCI)/Beth Israel Hospital (BIH) remain progression-free. This study determined factors prognostic for prolonged progression-free survival (PFS). METHODS From June 1988 to January 1992, who responded standard received cyclophosphamide, thiotepa, and carboplatin autotransplantation. Data encompassing initial...

10.1200/jco.1995.13.8.2043 article EN Journal of Clinical Oncology 1995-08-01

PURPOSE Immunotoxins could improve outcome in small-cell lung cancer (SCLC) by targeting tumor cells that are resistant to chemotherapy and radiation. N901 is a murine monoclonal antibody binds the CD56 (neural cell adhesion molecule [NCAM]) antigen found on of neuroendocrine origin, including SCLC. N901-bR an immunoconjugate with blocked ricin (bR) as cytotoxic effector moiety. has more than 700-fold greater selectivity vitro for killing CD56+ SCLC line SW-2 antigen-negative lymphoma line....

10.1200/jco.1997.15.2.723 article EN Journal of Clinical Oncology 1997-02-01

Traumatic brain injury (TBI) is common among military veterans and has been associated with an increased risk of dementia. It unclear if this due to for Alzheimer's disease (AD) or other mechanisms. This case control study sought evidence AD, as defined by the 2018 National Institute on Aging - Association (NIA-AA) research framework, measuring tau, β-amyloid, glucose metabolism using positron emission tomography (PET) in service-related TBI. Seventy male Vietnam war veterans—40 TBI (age...

10.1089/neu.2022.0172 article EN Journal of Neurotrauma 2023-03-01

2-[18F]fluoro-2-Deoxy-D-glucose (FDG) positron emission tomography (PET) may assist the diagnosis of dementia but it is an expensive investigation.To obtain management impact data for FDG-PET in dementia.This was a prospective study 194 consecutive patients referred from memory clinic at discretion specialists. Diagnosis and plans formulated multidisciplinary patient review meeting were compared before after release PET findings.FDG-PET had moderate to high on 85 (44%) participants. changed...

10.3233/jad-132729 article EN Journal of Alzheimer s Disease 2014-09-16

10531 Background: The efficacy of sorafenib in sarcomas was suggested a phase I study solid tumors. We conducted multicenter, II sarcoma patients (pts) with six histologic strata (leiomyosarcoma [LMS], MFH, MPNST, vascular [Angio], synovial sarcoma, other). Methods: Adults had received 0–1 prior lines therapy, needed good organ function and ECOG PS 0–2. Starting dose 400 mg oral BID. A Simon two-stage design used for each arm the 6-arm study. If 1 12 pts on RECIST PR, 25 more were accrued....

10.1200/jco.2008.26.15_suppl.10531 article EN Journal of Clinical Oncology 2008-05-20

Abstract Background T-DM1 is an antibody-drug conjugate that combines the biological activity of trastuzumab with targeted delivery anti-microtubule agent to HER2-expressing cancer cells. monotherapy effective and well tolerated in pts pretreated HER2-positive MBC. Nonclinical data suggest synergy for combination taxanes as P. Methods This 3+3 design phase Ib study (T-DM1 4652g) investigates tolerability dose-limiting toxicities (DLTs) (q3w q1w), T (q1w) P (q3w). Part 1 consisted q3w q1w...

10.1158/0008-5472.sabcs10-p3-14-10 article EN Cancer Research 2010-12-01

10004 Background: Preclinical and clinical data suggest that cixutumumab (IMC-A12), a fully human IgG1 monoclonal antibody, specifically targets the insulin growth factor-1 receptor (IGF-IR) with high affinity antagonizes IGF-I -II ligand binding signaling. Cixutumumab inhibits proliferation of variety tumor cell lines (Cancer Res. 2003;63:8912; Clin Cancer 2005;11:3065) may have role in treatment soft tissue sarcomas Ewing family tumors (ES/PNET). Methods: This 5-tier, phase II study single...

10.1200/jco.2011.29.15_suppl.10004 article EN Journal of Clinical Oncology 2011-05-20

Epidemiological studies suggest a relationship between posttraumatic stress disorder (PTSD) and dementia. This study assessed whether Alzheimer's disease (AD) imaging biomarkers were elevated in Vietnam veterans with PTSD. The compared cognition, amyloid-β, tau, regional brain metabolism volumes, the effect of APOE 83 without PTSD defined by Clinician-Administered Scale. group had significantly lower education, predicted premorbid IQ, total intracranial volume, Montreal Cognitive Assessment...

10.3233/jad-190913 article EN Journal of Alzheimer s Disease 2019-11-18
Coming Soon ...